Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENESTKorea: Nilotinib in Ph+ CML-CP
NCT03332511Phase 4Completed
- Sponsor
- Seoul National University Hospital
- Start
- May 2013
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Seoul National University Hospital. Primary endpoint: Cumulative rate of molecular response 4.5 at 24 months. Started May 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03332511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332511.